Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Drug

Moderna Announces Immunogenicity of Updated COVID-19 Vaccine Against New Variants

Fineline Cube Aug 18, 2023

Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2...

Company

Tigermed Establishes International Headquarters in Hong Kong to Accelerate Global Expansion

Fineline Cube Aug 18, 2023

China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of...

Company Medical Device

NMPA Approves Rapid Medical Ltd’s Intracranial Thrombectomy Stent for Marketing

Fineline Cube Aug 18, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Rapid Medical Ltd for...

Company Drug

Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug

Fineline Cube Aug 18, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...

Company Deals

CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology

Fineline Cube Aug 18, 2023

Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study

Fineline Cube Aug 18, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...

Company

Aurisco Pharmaceutical Passes US FDA cGMP Inspection at Jiangsu Plant

Fineline Cube Aug 17, 2023

China-based Aurisco Pharmaceutical (SHA: 605116) has announced the successful completion of a current Good Manufacturing...

Company Deals

Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment

Fineline Cube Aug 17, 2023

Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second...

Company

Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts

Fineline Cube Aug 17, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...

Company Drug

CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia

Fineline Cube Aug 17, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...

Company Drug

Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment

Fineline Cube Aug 17, 2023

China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...

Company Drug

European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults

Fineline Cube Aug 17, 2023

The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...

Company Drug

BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC

Fineline Cube Aug 17, 2023

Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...

Company Drug

Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Aug 17, 2023

Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...

Company Drug

Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer

Fineline Cube Aug 17, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Deals

Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform

Fineline Cube Aug 17, 2023

US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...

Company Digital

JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report

Fineline Cube Aug 17, 2023

JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...

Company

Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law

Fineline Cube Aug 17, 2023

Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...

Company Drug

Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis

Fineline Cube Aug 16, 2023

China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...

Company

Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom

Fineline Cube Aug 16, 2023

Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...

Posts pagination

1 … 469 470 471 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.